Study to Explore the Therapeutic Benefit of Intranasal Levodopa in Parkinson’s Disease OFF Reversal (THOR 201) SEATTLE, May 31, 2018 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of a Phase IIa study designed to explore...

Our CEO, Jon Congleton, will be speaking on June 12 at Xconomy’s annual Seattle-area life sciences conference at Cambia Grove in downtown Seattle. The event will look at what’s hot, and what’s next, for the Puget Sound region’s life sciences scene. For more information, visit the event webpage here. For more information, visit...

Sutapa Ray will be attending BIO 2018 on June 4 - 6th  in Boston, MA and will be available for partnering meetings. For more information, visit the BIO 2018 webpage here. ...

April 4, 2018 -- The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company’s Precision Olfactory Delivery™ or POD™ technology. Patent number 9,919,117, entitled “NOZZLES FOR NASAL DRUG DELIVERY,” is directed to nozzles used in the POD™ technology to allow drug...

Impel co-founder and CSO, Dr. John Hoekman, presented today at 11:00 AM on a panel discussing, "What’s New in Alzheimer’s and Other Neurodegenerative Diseases?" at Life Science Innovation Northwest 2018 in Seattle, WA. The panel was moderated by Dr. Adrian Hobden, President & CEO of CereSpir. Dr. John Hoekman was joined by Dr. Leen Kawas, President & CEO...

Impel's CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, will be presenting at Cowen's 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14th from 1:30 - 1:55 PM EDT. For more information, visit www.cowen.com/capabilities/conferences-events. ...

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...

Impel raises Series B round to commercialize POD technology platform and Impel’s growing portfolio of enhanced CNS products SEATTLE, October 14, 2015 -- Impel NeuroPharma Inc., (Impel) today announced the first close in its Series B financing round to commercialize the company’s revolutionary Precision Olfactory Delivery (POD) technology for the enhanced...